WALTHAM, Mass.--(BUSINESS WIRE)--March 9, 2006--PRAECIS PHARMACEUTICALS INCORPORATED (NASDAQ: PRCS) today announced that it is presenting preclinical data on its investigational compound, PPI-2458, at the GTC bio Angiogenesis Research & Therapeutics Conference being held in San Diego, California. The Company's presentation, entitled "Molecularly Targeted Therapy for Angiogenesis and Hyperproliferative Diseases through Inhibition of MetAP-2," will be delivered by Gerhard Hannig, Ph.D., Director of Cell Biology, Preclinical Research today at 11:00 a.m., PST. Dr. Hannig will present preclinical data supporting the Company's rationale for studying its investigational compound PPI-2458 as a targeted molecular therapy with potential disease-modifying activity in rheumatoid arthritis. A copy of the presentation will be posted on the Company's website at http://www.praecis.com, under "Investors" following the presentation.
